SEC Form 8-K filed by Silence Therapeutics Plc
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 2, 2025
Silence Therapeutics plc
(Exact name of registrant as specified in its Charter)
| England and Wales | 001-39487 | Not Applicable | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 72 Hammersmith Road London United Kingdom |
W14 8TH | |
| (Address of principal executive offices) | (Zip Code) |
+44 20 3457 6900
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share | SLN | The Nasdaq Stock Market LLC | ||
| Ordinary share, nominal value £0.05 per share* | * | The Nasdaq Stock Market LLC |
| * | Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01. | Regulation FD Disclosure. |
Domestic Issuer Status
Effective January 1, 2025, Silence Therapeutics plc (the “Company”) will begin to file periodic reports and registration statements on U.S. domestic issuer forms with the U.S. Securities and Exchange Commission, which are more detailed and extensive in certain respects, and which must be filed more promptly, than the forms available to a “foreign private issuer” as defined in Rule 405 under the Securities Act of 1933, as amended. Prior to January 1, 2025, the Company qualified as a foreign private issuer.
Disclosure Channels to Disseminate Information
The Company announces material information to the public about the Company, its potential product candidates Zerlasiran and Divesiran, its pipeline and the Company’s mRNAi GOLD™ platform and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission, press releases, public conference calls, the Company’s website (www.silence-therapeutics.com), the investor relations section of its website (www.silence-therapeutics.com/investors), and/or social media, including its LinkedIn account (www.linkedin.com/company/silence-therapeutics-plc) and X account (formerly known as “Twitter”) (@SilenceTheraPlc), in order to achieve broad, non-exclusionary distribution of information to the public. The Company encourages investors and others to review the information it makes public in these locations, as such information could be deemed to be material information. Please note that this list may be updated from time to time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SILENCE THERAPEUTICS PLC | ||||||
| Dated: January 2, 2025 | By: | /s/ Craig Tooman | ||||
| Name: Craig Tooman | ||||||
| Title: Chief Executive Officer | ||||||